Bayer (FRA:BAYN)‘s stock had its “buy” rating reiterated by equities research analysts at Citigroup in a note issued to investors on Thursday.
A number of other research firms also recently commented on BAYN. S&P Global set a €126.00 ($150.00) target price on shares of Bayer and gave the company a “buy” rating in a research report on Thursday, October 26th. Sanford C. Bernstein set a €131.00 ($155.95) target price on shares of Bayer and gave the company a “buy” rating in a research report on Wednesday, November 29th. DZ Bank reissued a “buy” rating on shares of Bayer in a research report on Monday, December 11th. equinet set a €118.00 ($140.48) target price on shares of Bayer and gave the company a “buy” rating in a research report on Friday, October 13th. Finally, BNP Paribas set a €130.00 ($154.76) target price on shares of Bayer and gave the company a “buy” rating in a research report on Monday, September 25th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the company. Bayer currently has an average rating of “Buy” and an average price target of €122.33 ($145.63).
Bayer (BAYN) opened at €105.60 ($125.71) on Thursday. The company has a market cap of $87,620.00 and a PE ratio of 28.31. Bayer has a 12 month low of €99.69 ($118.68) and a 12 month high of €123.82 ($147.40).
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/11/bayer-bayn-earns-buy-rating-from-citigroup.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.